Bio Sidus Sa
Clinical trials sponsored by Bio Sidus Sa, explained in plain language.
-
Biosimilar switch for fabry disease shows promise in small trial
Disease control CompletedThis study tested whether a new, similar version of the drug agalsidase beta (called AGA BETA BS) works as well as the standard drug Fabrazyme in people with Fabry disease. Twenty adults who were already stable on Fabrazyme switched to the new drug for 6 months to a year. The mai…
Phase: PHASE3 • Sponsor: Bio Sidus SA • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Healthy men test generic version of rare disease drug
Knowledge-focused CompletedThis study tested a new version of the drug agalsidase beta (made by Biosidus) against the approved version (Fabrazyme) in 24 healthy men. The goal was to see if the new version behaves similarly in the body. This is an early-stage study that does not directly treat patients with…
Phase: PHASE1 • Sponsor: Bio Sidus SA • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC